ClinicalTrials.gg
RecruitingNCT05543941XPERIENCEUpdated May 28, 2026

Evaluating XPERIENCE™ Advanced Surgical Irrigation

An interventional study of XPERIENCE Advanced Surgical Irrigation and Dilute Betadine in Hip Osteoarthritis, Hip Arthritis and Knee Osteoarthritis, sponsored by Ottawa Hospital Research Institute. Recruiting at 8 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Ottawa Hospital Research Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
7,600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Osteoarthritis, Hip with a site in Canada — 9 open to participants now, 13 under way, none of them phase 3. Osteoarthritis, Hip · Canada.

Planned enrollment
Largest of 41
7,600 · median 96
Started
2023
with 6 others
No phase
32 of 49
8 open now
Primary completion
2027-03
later than 6 of 12 live
Registered
39th of 49
by date
Lead sponsor
4 of 49
Ottawa Hospital Research Institute

Among the 49 studies in Osteoarthritis, Hip with a site in Canada, this one has the largest planned enrollment of the 41 interventional ones that give a count, is one of 7 that started in 2023, is one of 32 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 39th registered.

Osteoarthritis, Hip

642 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.

Browse Osteoarthritis, Hip studies →

Open to participants now

9 of the 49 studies in Osteoarthritis, Hip with a site in Canada are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 86 Osteoarthritis, Hip studies recruiting now, 53 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Osteoarthritis, Hip with a site in Canada, or all of them as a file.
02

Study summary

A prospective, multi-center, double-arm, parallel, interventional, randomized, controlled clinical trial to assess the rate of periprosthetic joint infection (PJI) in patients undergoing primary total knee arthroplasty (TKA), total hip arthroplasty (THA) or hip resurfacing (HR) with XPERIENCE™ (XP) Advanced Surgical Irrigation versus dilute Betadine (DB).

03

Conditions studied

  • Hip Osteoarthritis
  • Hip Arthritis
  • Knee Osteoarthritis
  • Knee Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged 18 years or older
  2. Diagnosis of osteoarthritis, inflammatory arthritis, osteonecrosis, or post-traumatic arthritis to the affected joint.
  3. Primary TKA, THA, and HR
  4. Subjects receiving both cemented or uncemented orthopaedic implants
  5. Willing and able to sign written consent, follow study protocol and attend follow-up

Exclusion criteria

Exclusion Criteria:

  1. Inability or refusal to sign form
  2. Non-English or French speaking, and no licensed translator, family member or substitute decision maker available.
  3. Prior arthroplasty procedure to the affected joint
  4. Procedures involving solid HA implants
  5. Oncologic diagnosis to the affected joint.
  6. Non-TKA, THA or HR prosthesis (i.e., hemiarthroplasty, unicompartmental arthroplasty etc.)
  7. Allergy to any of the components of XP Advanced Surgical Irrigation
  8. Allergy to iodine
  9. Presence of concurrent active infection, primary immunodeficiency, history of uncontrolled ( \<200 cells/uL), treatment with immunomodulatory medications for or disease (with exception to inflammatory arthritis), chronic glucocorticosteroid use (≥20 mg of prednisone daily for at least 1 month with another cause of ), and solid organ and/or bone marrow transplantation.
  10. History of septic arthritis to the affected joint within two years of surgery(1).
  11. History of injection to the affected joint within the three months preceding surgery.
  12. Simultaneous bilateral total joint arthroplasty
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
7,600 participants (estimated)

Study arms

  • Experimental
    XPERIENCE Advanced Surgical Irrigation

    Patients will receive the XPERIENCE Advanced Surgical Irrigation prior to wound closure.

    Device: XPERIENCE Advanced Surgical Irrigation

  • Active comparator
    Dilute Betadine

    Patients will receive Dilute Betadine solution prior to wound closure.

    Device: Dilute Betadine

Interventions

  • DeviceXPERIENCE Advanced Surgical Irrigation

    The patient will undergo THA, TKA, or HR with irrigation of the deep wound prior to fascial closure consisting of XPERIENCE Advanced Surgical Irrigation (XP). XP solution will be applied prior to fascial closure and left to soak for up to 3 minutes. Remaining product will be suctioned away throughout the procedure. No rinsing should take place after irrigation and surgical site will be closed according to site standard operating procedures.

    Also known as: XP

  • DeviceDilute Betadine

    The patient will undergo THA, HR or TKA with irrigation of the deep wound prior to fascial closure consisting of Dilute Betadine (DB). DB concentration will be standardized at 0.3% povidone-iodine. DB will be prepared by combining 30 mL of sterile 10% povidone-iodine (from a sterile catheter pack) with 1 L of 0.9% saline in a sterile splash basin. Solution will be left to soak for up to 3 minutes and remaining povidone-iodine solution will be suctioned away. Area will then be rinsed with 1L of normal saline. Surgical site will be closed according to site standard operating procedures.

    Also known as: DB, Providone-Iodine

06

What researchers measure

Primary outcomes

  1. Rate of acute (<90 days post-surgery) PJI

    Number of patients diagnosed with periprosthetic joint infection as per the diagnostic criteria outlined by the 2018 International Consensus Meeting of the Musculoskeletal Infection Society for Acute PJI.

    Time frame: 2 weeks after surgery, 3 months after surgery, within 90 day of surgery

Secondary outcomes

  1. Rate of Superficial Wound Infections

    Number of superficial wound infections

    Time frame: 2 weeks after surgery

  2. Rate of PJI at 1 year

    Number of patients diagnosed with periprosthetic joint infections at 1 year after surgery

    Time frame: 12 months after surgery

  3. Subgroup analysis of PJI rates for high-risk patients

    Number of patients diagnosed with PJI at 3 months and 1 year in higher risk patient categories (morbid obesity (BMI \>40kg/m2), diabetes mellitus, chronic kidney disease, inflammatory arthritis, active smokers (nicotine))

    Time frame: 3 months after surgery, 12 months after surgery

  4. Patient Reported Functional Outcome Scores

    As measured by the Oxford Hip Score (OHS) or Oxford Knee Score (OKS)

    Time frame: Before surgery, 3 months after surgery, 12 months after surgery

  5. Patient Reported Quality of Life Scores

    As measured by the Patient-Reported Outcomes Measurement Information System (PROMIS)

    Time frame: Before surgery, 3 months after surgery, 12 months after surgery

  6. Wound Complications (non-infection) requiring revision surgery

    Number of patients requiring a revision surgery for a non-infection related wound complication

    Time frame: 2 weeks after surgery

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No IPD will be made available to other researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Mar 2027, 47 months after the start.

Of 201 non-industry interventional studies with no phase under Osteoarthritis, Hip, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 47 months is above that.

Counting every sponsor, half of 227 studies reached it within 29 months; a quarter within 14 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2022
First posted
Sep 16, 2022
StartActual
Apr 1, 2023
Primary completionEst.
Mar 31, 2027
CompletionEst.
Dec 31, 2027
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05543941
Collaborators
OsteoRemedies, LLC
Responsible party
Sponsor
First posted
Sep 16, 2022
Start date
Apr 1, 2023
Primary completion
Mar 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 28, 2026

Study contacts

Sanjula Costa
Contact
scosta@ohri.ca
613-737-8899 ext. 72640
Simon Garceau, MD
principal investigator · The Ottawa Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion